Physician profile
James D Izer
NPI 1861400418
$6,077.43
in general payments reported to CMS, 2019-2025
22 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $2,268 · 2021: $591 · 2022: $513 · 2023: $376 · 2024: $316 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $2,543.11 | 2019-2021 | |
| Allergan, INC. | $1,040.77 | 2019-2022 | |
| Abbvie INC. | $465.09 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $373.92 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $330.45 | 2021-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $325.75 | 2019-2021 | |
| Alcon Vision LLC | $280.75 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Novartis Pharmaceuticals Corporation | $191.09 | 2019-2023 | |
| Oyster Point Pharma, INC. | $82.25 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $62.10 | 2025 | Vevye |
| Omeros Corporation | $56.62 | 2019 | |
| Aerie Pharmaceuticals, INC. | $52.12 | 2019-2021 | |
| Rxsight INC | $42.66 | 2024-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Akorn, INC. | $41.35 | 2020 | |
| Thea Pharma INC. | $38.66 | 2025 | Iyuzeh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $27.35 | 2022 | |
| Sight Sciences, INC. | $24.98 | 2023 | Tearcare System |
| Akorn Operating Company LLC | $24.60 | 2021 | |
| Merz Pharmaceuticals, LLC | $19.42 | 2022 | |
| Alcon Research LLC | $18.82 | 2019 | |
| Glaukos Corporation | $17.79 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $17.78 | 2023 | Acuvue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Izer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.